312 related articles for article (PubMed ID: 28445455)
1. Structural insight into allosteric modulation of protease-activated receptor 2.
Cheng RKY; Fiez-Vandal C; Schlenker O; Edman K; Aggeler B; Brown DG; Brown GA; Cooke RM; Dumelin CE; Doré AS; Geschwindner S; Grebner C; Hermansson NO; Jazayeri A; Johansson P; Leong L; Prihandoko R; Rappas M; Soutter H; Snijder A; Sundström L; Tehan B; Thornton P; Troast D; Wiggin G; Zhukov A; Marshall FH; Dekker N
Nature; 2017 May; 545(7652):112-115. PubMed ID: 28445455
[TBL] [Abstract][Full Text] [Related]
2. Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition.
Kennedy AJ; Sundström L; Geschwindner S; Poon EKY; Jiang Y; Chen R; Cooke R; Johnstone S; Madin A; Lim J; Liu Q; Lohman RJ; Nordqvist A; Fridén-Saxin M; Yang W; Brown DG; Fairlie DP; Dekker N
Commun Biol; 2020 Dec; 3(1):782. PubMed ID: 33335291
[TBL] [Abstract][Full Text] [Related]
3. The development of proteinase-activated receptor-2 modulators and the challenges involved.
McIntosh KA; Cunningham MR; Bushell T; Plevin R
Biochem Soc Trans; 2020 Dec; 48(6):2525-2537. PubMed ID: 33242065
[TBL] [Abstract][Full Text] [Related]
4. Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery.
Perry SR; Xu W; Wirija A; Lim J; Yau MK; Stoermer MJ; Lucke AJ; Fairlie DP
J Chem Inf Model; 2015 Jun; 55(6):1181-91. PubMed ID: 26000704
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist.
Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN
J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555
[TBL] [Abstract][Full Text] [Related]
6. Protease-activated receptor 2 (PAR-2) antagonist AZ3451 as a novel therapeutic agent for osteoarthritis.
Huang X; Ni B; Xi Y; Chu X; Zhang R; You H
Aging (Albany NY); 2019 Dec; 11(24):12532-12545. PubMed ID: 31841119
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.
Gandhi DM; Majewski MW; Rosas R; Kentala K; Foster TJ; Greve E; Dockendorff C
Bioorg Med Chem; 2018 May; 26(9):2514-2529. PubMed ID: 29685684
[TBL] [Abstract][Full Text] [Related]
8. Mapping transmembrane residues of proteinase activated receptor 2 (PAR
Suen JY; Adams MN; Lim J; Madala PK; Xu W; Cotterell AJ; He Y; Yau MK; Hooper JD; Fairlie DP
Pharmacol Res; 2017 Mar; 117():328-342. PubMed ID: 27993717
[TBL] [Abstract][Full Text] [Related]
9. Biased signaling: potential agonist and antagonist of PAR2.
Kakarala KK; Jamil K
J Biomol Struct Dyn; 2016 Jun; 34(6):1363-76. PubMed ID: 26295578
[TBL] [Abstract][Full Text] [Related]
10. Pathway-selective antagonism of proteinase activated receptor 2.
Suen JY; Cotterell A; Lohman RJ; Lim J; Han A; Yau MK; Liu L; Cooper MA; Vesey DA; Fairlie DP
Br J Pharmacol; 2014 Sep; 171(17):4112-24. PubMed ID: 24821440
[TBL] [Abstract][Full Text] [Related]
11. Allosteric modulation of protease-activated receptor signaling.
Canto I; Soh UJ; Trejo J
Mini Rev Med Chem; 2012 Aug; 12(9):804-11. PubMed ID: 22681248
[TBL] [Abstract][Full Text] [Related]
12. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110).
Suen JY; Barry GD; Lohman RJ; Halili MA; Cotterell AJ; Le GT; Fairlie DP
Br J Pharmacol; 2012 Mar; 165(5):1413-23. PubMed ID: 21806599
[TBL] [Abstract][Full Text] [Related]
13. Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).
Yau MK; Lim J; Liu L; Fairlie DP
Expert Opin Ther Pat; 2016; 26(4):471-83. PubMed ID: 26936077
[TBL] [Abstract][Full Text] [Related]
14. The PAR2 signal peptide prevents premature receptor cleavage and activation.
Liu B; Lee G; Wu J; Deming J; Kuei C; Harrington A; Wang L; Towne J; Lovenberg T; Liu C; Sun S
PLoS One; 2020; 15(2):e0222685. PubMed ID: 32078628
[TBL] [Abstract][Full Text] [Related]
15. High-resolution crystal structure of human protease-activated receptor 1.
Zhang C; Srinivasan Y; Arlow DH; Fung JJ; Palmer D; Zheng Y; Green HF; Pandey A; Dror RO; Shaw DE; Weis WI; Coughlin SR; Kobilka BK
Nature; 2012 Dec; 492(7429):387-92. PubMed ID: 23222541
[TBL] [Abstract][Full Text] [Related]
16. Toward drugs for protease-activated receptor 2 (PAR2).
Yau MK; Liu L; Fairlie DP
J Med Chem; 2013 Oct; 56(19):7477-97. PubMed ID: 23895492
[TBL] [Abstract][Full Text] [Related]
17. A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells.
Jiang Y; Yau MK; Lim J; Wu KC; Xu W; Suen JY; Fairlie DP
J Pharmacol Exp Ther; 2018 Feb; 364(2):246-257. PubMed ID: 29263243
[TBL] [Abstract][Full Text] [Related]
18. Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activity.
Giblin P; Boxhammer R; Desai S; Kroe-Barrett R; Hansen G; Ksiazek J; Panzenbeck M; Ralph K; Schwartz R; Zimmitti C; Pracht C; Miller S; Magram J; Litzenburger T
Hum Antibodies; 2011; 20(3-4):83-94. PubMed ID: 22129678
[TBL] [Abstract][Full Text] [Related]
19. Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2.
Lieu T; Savage E; Zhao P; Edgington-Mitchell L; Barlow N; Bron R; Poole DP; McLean P; Lohman RJ; Fairlie DP; Bunnett NW
Br J Pharmacol; 2016 Sep; 173(18):2752-65. PubMed ID: 27423137
[TBL] [Abstract][Full Text] [Related]
20. Structure and putative signaling mechanism of Protease activated receptor 2 (PAR2) - a promising target for breast cancer.
Kakarala KK; Jamil K; Devaraji V
J Mol Graph Model; 2014 Sep; 53():179-199. PubMed ID: 25173751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
